Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 1-3

  Bristow, Robert E ^a  

^a Kelly Gynecologic Oncology Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CYTOREDUCTIVE SURGERY; EDITORIAL; LENGTH OF STAY; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL;

CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 57649088472     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.002     Document Type: Editorial

References (12)

1. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
2. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 (2006) 77-85
3. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
4. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol. Oncol. 77 (2000) 227-231
5. Vorgias G., Iavazzo C., Savvopoulos P., Myriokefalitaki E., Katsoulis M., Kalinoglu N., and Akrivos T. Can the preoperative CA-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol. Oncol. 112 (2009) 11-15
6. Chi D.S., Zivanovic O., Palayekar M.J., Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Leitao M.M., Brown C.L., and Barakat R.R. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol. Oncol. 112 (2009) 6-10
7. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnigin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
8. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 (2006) 1083-1090
9. Zivanovic O., Eisenhauer E.L., Zhou Q., Iasonos A., Sabbatini P., Sonoda Y., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 108 (2008) 287-292
10. May M.E. The elegant solution. Toyota's formula for mastering innovation (2007), Free Press, New York, New York
11. Cliby W., Dowdy S., Feitoza S.S., Gostout B.S., and Podratz K.C. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol. Oncol. (2004) 655-660
12. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25 (2007) 384-389